1. Jon Holmes

    0 Comments Leave a Comment

    1-15 of 93 1 2 3 4 5 6 7 »
    1. Mentioned In 93 Articles

    2. Dynamic optical coherence tomography of skin blood vessels – proposed terminology and practical guidelines

      Dynamic optical coherence tomography of skin blood vessels – proposed terminology and practical guidelines
      Background Dynamic optical coherence tomography (D-OCT) has recently been introduced in dermatology. In contrast to Standard OCT imaging, which exclusively relies on the morphological analysis of the tissue, D-OCT allows the in-vivo visualisation of blood flow. Preliminary D-OCT data showed differences in the vascularisation of nevus to melanoma transition, suggesting that this technology may help to differentiate between benign and malignant lesions. Objective Several factors may influence the quality of ...
      Read Full Article
    3. Adoption Depends on Meeting Clinical Needs

      Comment "This is a topic I have spoke on for decades. As a physician, OCT researcher, and co-founder of Lightlab Imaging, ..." - mebrezin
      Adoption Depends on Meeting Clinical Needs
      Every year, I am amazed and impressed by the number and variety of presentations at conferences in the field of biophotonics . We are blessed by the seemingly endless ways to manipulate and measure light, relatively inexpensively, in our pursuit of powerful new ways to understand, diagnose and treat disease. Much human ingenuity has been applied to overcoming difficult technical problems and pushing back the bounds of our knowledge. But then ...
      Read Full Article
    4. In vivo microvascular imaging of cutaneous actinic keratosis, Bowen's disease and squamous cell carcinoma using Dynamic optical coherence tomography

      In vivo microvascular imaging of cutaneous actinic keratosis, Bowen's disease and squamous cell carcinoma using Dynamic optical coherence tomography
      Background A clear distinction between actinic keratosis (AK), Bowen's disease (BD) and squamous cell carcinoma (SCC) cannot reliably be made by clinical and dermoscopic evaluation alone. Dynamic optical coherence tomography (D-OCT) is a novel angiographic variant of OCT that allows for non-invasive, in vivo evaluation of the cutaneous microvascular morphology. Objective To investigate the microvascular structures of AK, BD and invasive SCC using D-OCT in order to gain insights ...
      Read Full Article
    5. Vascular Features of Nail Psoriasis Using Dynamic Optical Coherence Tomography

      Vascular Features of Nail Psoriasis Using Dynamic Optical Coherence Tomography
      Background: Nail psoriasis is a painful and disfiguring nail disease that often leads to invasive biopsies. Dermoscopy of the hyponychium can be useful in the diagnosis showing twisted coiled vessels. Structural features of nail psoriasis have been described with optical coherence tomography (OCT). Objectives: To investigate vascular features of nail psoriasis using dynamic OCT. Methods: This was an observational, prospective, controlled study in which psoriasis patients with psoriatic nail changes ...
      Read Full Article
    6. Validation of Dynamic optical coherence tomography for non-invasive, in vivo microcirculation imaging of the skin

      Validation of Dynamic optical coherence tomography for non-invasive, in vivo microcirculation imaging of the skin
      Objectives Dynamic optical coherence tomography (D-OCT) is anangiographic variation of OCT that non-invasively provides images of the in vivo microvasculature of the skin by combining conventional OCT images with flow data. The objective of this study was to investigate and report on the D-OCT technique for imaging of the vascular networks in skin as well as to validate the method by comparing the results against already accepted blood flow measuring ...
      Read Full Article
    7. VivoSight OCT used to visualize vascular networks in melanoma and non-melanoma skin cancers

      VivoSight OCT used to visualize vascular networks in melanoma and non-melanoma skin cancers
      Maidstone, UK, 3rd May 2016 New results have been published in Dermatology Online demonstrating that Michelson Diagnostics VivoSight OCT scanner can be used to image the blood vessel networks grown by skin cancers, and showing that skin lesions could be differentiated using their characteristic vascular patterns. This new technology may become a powerful tool in the dermatologistss toolkit for the diagnosis of skin cancer and other conditions. The paper, entitled ...
      Read Full Article
    8. Dynamic Optical Coherence Tomography in Dermatology

      Dynamic Optical Coherence Tomography in Dermatology
      Optical coherence tomography (OCT) represents a non-invasive imaging technology, which may be applied to the diagnosis of non-melanoma skin cancer and which has recently been shown to improve the diagnostic accuracy of basal cell carcinoma. Technical developments of OCT continue to expand the applicability of OCT for different neoplastic and inflammatory skin diseases. Of these, dynamic OCT (D-OCT) based on speckle variance OCT is of special interest as it allows ...
      Read Full Article
    9. Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis

      Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis
      ...nal image is an unrivalled benefit for my orientation and medical decision making ” – Dr Heckmann, Starnberg Jon Holmes, CEO of Michelson Diagnostics, added “Our VivoSight OCT scanner is already proving popular with Der...
      Read Full Article
    10. Michelson Diagnostics to present at Fortbildungswoche, Munich

      Michelson Diagnostics to present at Fortbildungswoche, Munich
      Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (OCT) technology, today announces that leading experts in the use of optical technology in dermatology will be presenting the benefits of multi-beam OCT at the 24th Annual Education Week for Practical Dermatology and Venereology, known as Fortbildungswoche, in Munich, Germany, 19-25 July 2014. The conference session on Evidence for OCT diagnostics will take place at 12 ...
      Read Full Article
    11. 1-15 of 93 1 2 3 4 5 6 7 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Jon Holmes

    Jon Holmes

    Jon D. Holmes is Founder & CTO of Michelson Diagnostics.

  3. Quotes

    1. Obtaining the Category III CPT code for OCT of the skin is an important step towards our goal of obtaining reimbursement and coverage, and we welcome the new codes that can be used by clinicians to record their clinical use of VivoSight OCT in their practice.
      In Michelson Diagnostics Secures CPT codes for Optical Coherence Tomography Imaging of Skin
    2. Jon Holmes, Co-Founder, Michelson Diagnostics, added: “delighted that Andy has joined the team at Michelson as CEO. Our ability to attract a CEO with such impressive credentials is a testament both to the team’s achievements to date and to the potential commercial opportunity of the VivoSight OCT system in non-melanoma skin cancer. With Andy now on board to spearhead our commercial growth, I look forward to driving the VivoSight OCT technology development and clinical validation into other clinical applications where we believe it can make a significant impact on patient diagnosis and treatment monitoring.
      In Andy Hill Appointed Chief Executive Officer of Michelson Diagnostics
    3. Our VivoSight OCT scanner is already proving popular with Dermatologists who are keen to deliver the best possible care to their non-melanoma skin cancer patients, and based on this initial feedback I am sure that the new improved probe with Micro-Camera will further accelerate the adoption of VivoSight OCT as a standard tool for the practising Dermatologist.
      In Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis
    4. We are delighted to be working with Dr Guitera and the Melanoma Institute of Australia. She is one of the top ten world experts in her field. We believe that our VivoSight system is the future of tumour diagnosis and monitoring and we looking forward to reporting the results in due course.
      In New study on non-invasive diagnosis of non-melanoma skin cancer with Melanoma Institute of Australia
    5. The positive results from our study clearly demonstrate the clinical benefits of using our VivoSight OCT system in the diagnosis and monitoring of basal cell carcinoma. We believe that VivoSight has the potential to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect the skin, and in particular non-melanoma skin cancers. We look forward to releasing the full data in due course.
      In Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT
    6. "We look forward to sharing the preliminary results from this important clinical study. It will hopefully provide level 1 evidence for the first time of the diagnostic value of OCT in dermatology and specifically its use in the detection of non-melanoma skin cancers such as basal cell carcinoma.”
      In Michelson Diagnostics announces completion of data collection in Vivosight OCT trial for BCC diagnosis
    7. We look forward to sharing the preliminary results from this important clinical study.
      In Michelson Diagnostics announces completion of data collection in Vivosight OCT trial for BCC diagnosis
    8. At Michelson Diagnostics, we strive to provide clinicians with cutting edge technology to enable accurate diagnosis of skin conditions. The additional functionality of this software places our VivoSight system at the forefront of dermatology diagnosis, reducing the need for biopsy and facilitating improved patient outcomes.
      In Michelson Diagnostics to launch enhanced software for VivoSight OCT scanner
    9. "We evaluated many available swept laser products when selecting a supplier for our new Vivosight system...We found Axsun to be the ideal company with whom to partner, offering the best platform of performance, value and volume manufacturing capability.
      In Axsun Technologies Announces Volume Purchase Order for Swept Laser Engines from Michelson Diagnostics Ltd.
    10. We are delighted to be the lead partner in the ADVANCE project. We believe this will be a significant development in the non-invasive diagnosis and monitoring of diseases and conditions that affect the skin. The capability to provide images of fine blood vessels in skin is likely to have many other clinical applications, such as monitoring treatment of inflammatory diseases and wound healing.
      In Michelson Diagnostics targets malignant melanoma using OCT imaging with €2.3M EU funding
  4. Quotes about Jon Holmes

    1. Jon Holmes, Chief Executive Officer of Michelson Diagnostics, commented
      In Michelson Diagnostics Announces £1.98 Million Financing
    2. Jon Holmes, Co-Founder, Michelson Diagnostics, added: “delighted that Andy has joined the team at Michelson as CEO. Our ability to attract a CEO with such impressive credentials is a testament both to the team’s achievements to date and to the potential commercial opportunity of the VivoSight OCT system in non-melanoma skin cancer. With Andy now on board to spearhead our commercial growth, I look forward to driving the VivoSight OCT technology development and clinical validation into other clinical applications where we believe it can make a significant impact on patient diagnosis and treatment monitoring.
      Jon Holmes in Andy Hill Appointed Chief Executive Officer of Michelson Diagnostics